Peers: WGS VCYT NTRA GH DGX LH A DHR TMO CSTL

| Held by: IWM VTI VB VXF IWN IBB VTWO VBR SCHA VBK

Index	RUT
Market Cap	1.02B
Enterprise Value	1.12B
Income	-72.89M
Sales	587.89M
Book/sh	1.59
Cash/sh	0.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2275
IPO	Nov 02, 1995

P/E	-
Forward P/E	-
PEG	-
P/S	1.73
P/B	0.86
P/C	3.38
P/FCF	-
EV/EBITDA	-
EV/Sales	1.90
Quick Ratio	2.93
Current Ratio	3.35
Debt/Eq	0.34
LT Debt/Eq	0.32
Option/Short	Yes / Yes

EPS (ttm)	-0.10
EPS next Y	-0.27
EPS next Q	-0.07
EPS this Y	24.44%
EPS next Y	-19.12%
EPS next 5Y	6.53%
EPS past 3/5Y	13.03% -
Sales past 3/5Y	-15.45% -15.82%
EPS Y/Y TTM	58.54%
Sales Y/Y TTM	-11.46%
EPS Q/Q	94.11%
Sales Q/Q	4.32%
Earnings	Jul 27 AMC
EPS/Sales Surpr.	87.50% 24.59%

Insider Own	48.59%
Insider Trans	0.00%
Inst Own	28.87%
Inst Trans	1.04%
ROA	-3.83%
ROE	-5.88%
ROIC	-4.67%
Gross Margin	27.75%
Oper. Margin	-28.56%
Profit Margin	-12.40%
SMA20	-12.58%
SMA50	-9.48%
SMA200	2.92%
Trades

Shs Outstand	745.95M
Shs Float	383.71M
Short Float	9.27%
Short Ratio	10.79
Short Interest	35.56M
52W High	1.75 -22.06%
52W Low	0.98 39.62%
Volatility	4.65% 3.54%
ATR (14)	0.06
RSI (14)	31.51
Beta	1.51
Rel Volume	0.49
Avg Volume	3.30M
Volume	362,833

Perf Week	-6.58%
Perf Month	-12.57%
Perf Quarter	13.66%
Perf Half Y	16.57%
Perf YTD	8.25%
Perf Year	-9.68%
Perf 3Y	1.03%
Perf 5Y	-63.43%
Perf 10Y	-85.73%
Recom	1.67
Target Price	4.38
Prev Close	1.38
Price	1.36
Change %	-1.17%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-29-26	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-20-25	Initiated	JP Morgan	Neutral
Oct-31-25	Downgrade	Jefferies	Buy → Hold	$1.60
Apr-25-25	Initiated	JP Morgan	Neutral
Jun-29-23	Upgrade	Barrington Research	Mkt Perform → Outperform	$2
Dec-15-22	Initiated	H.C. Wainwright	Buy	$3
Jan-24-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-21-21	Initiated	Ladenburg Thalmann	Buy	$7
Nov-25-19	Initiated	Piper Jaffray	Overweight	$2.50
Mar-02-18	Downgrade	JP Morgan	Neutral → Underweight
Sep-14-17	Downgrade	JP Morgan	Overweight → Neutral
Jun-21-16	Reiterated	Standpoint Research	Buy	$16 → $18
Jun-03-16	Initiated	Standpoint Research	Buy	$16
Mar-31-16	Reiterated	Barrington Research	Outperform	$17 → $16
Oct-16-15	Initiated	JP Morgan	Overweight	$14
Sep-11-15	Downgrade	Jefferies	Buy → Hold
Mar-03-15	Downgrade	Oppenheimer	Outperform → Perform
May-12-14	Reiterated	Oppenheimer	Outperform	$13 → $12
Mar-14-14	Initiated	Oppenheimer	Outperform	$13
Nov-13-13	Reiterated	Ladenburg Thalmann	Buy	$10 → $14.50

Show Previous Ratings

Sep-08-26 01:55PM	OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
Aug-31-26 11:39AM	Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge)
Aug-13-26 09:15AM	OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests (GlobeNewswire)
Jul-28-26 08:30AM	OPKO Health, Inc. Q2 2026 Earnings Call Summary (Moby) +33.06%
01:01AM	OPKO Health Inc (OPK) Q2 2026 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
04:18PM	Loading…
Jul-27-26 04:18PM	OPKO Health: Q2 Earnings Snapshot (Associated Press)
04:05PM	OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results (GlobeNewswire)
Jul-23-26 12:30PM	OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026 (GlobeNewswire)
Jun-15-26 08:00AM	Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026 (GlobeNewswire)
May-12-26 08:00AM	OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies (GlobeNewswire)
Apr-30-26 08:30AM	OPKO Health Expands Nicoya Agreement to Support RAYALDEE Commercialization in Greater China (GlobeNewswire)
08:00AM	BioReference Launches BioReference Direct, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform (GlobeNewswire)
Apr-29-26 03:09AM	OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... (GuruFocus.com) -8.26%
Apr-28-26 04:48PM	OPKO Health: Q1 Earnings Snapshot (Associated Press)
04:05PM	OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	Loading…
Apr-22-26 08:00AM	OPKO Health's ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas (GlobeNewswire)
Apr-21-26 04:05PM	OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026 (GlobeNewswire)
Apr-08-26 08:00AM	OPKO Health's ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19 (GlobeNewswire)
Feb-27-26 12:48PM	OPK Q4 Earnings & Revenues Beat Estimates, Gross Margin Contracts (Zacks)
08:30AM	OPKO Health, Inc. Q4 2025 Earnings Call Summary (Moby)
08:00AM	OPKO Health to Participate in the Jefferies Biotech on the Beach Summit (GlobeNewswire)
01:12AM	OPKO Health Q4 Earnings Call Highlights (MarketBeat)
12:06AM	OPKO Health Inc (OPK) Q4 2025 Earnings Call Highlights: Strategic Divestitures and Promising ... (GuruFocus.com)
Feb-26-26 07:00PM	Compared to Estimates, OPKO Health (OPK) Q4 Earnings: A Look at Key Metrics (Zacks)
06:45PM	OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:34PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Fourth Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Feb-18-26 10:39AM	Can OPKO Health's Pipeline Progress and Deals Drive Growth in 2026? (Zacks)
Feb-17-26 08:42PM	Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation (Insider Monkey)
Feb-12-26 08:00AM	OPKO Health to Report Fourth Quarter 2025 Financial Results on February 26 (GlobeNewswire)
11:02AM	Loading…
Feb-06-26 11:02AM	Opko Health (OPK) Expands Entera Partnership for Drug Co-Development (Insider Monkey)
Feb-04-26 08:00AM	OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism (GlobeNewswire)
Jan-13-26 04:43AM	OrthoPediatrics (KIDS) Moves 9.8% Higher: Will This Strength Last? (Zacks)
Jan-06-26 04:11PM	OPKO Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
07:05AM	OPKO Health Bets on RAYALDEE and Pipeline Progress for 2026 Growth (Zacks)
Dec-09-25 07:28AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now (Zacks)
Nov-20-25 09:40AM	Astera initiated, Nasdaq upgraded: Wall Street's top analyst calls (The Fly)
Nov-19-25 04:05PM	OPKO Health to Participate in the Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 08:03AM	NextPlat Reports Third Quarter 2025 Results (PR Newswire)
Oct-30-25 11:29PM	Opko Health Inc.'s (OPK) ModeX Therapeutics Announces License and Collaboration Agreement With Regeneron Pharmaceuticals (Insider Monkey) -6.85%
12:24PM	OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands (Zacks)
Oct-29-25 06:30PM	Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics (Zacks)
05:40PM	OPKO Health (OPK) Q3 Earnings Surpass Estimates (Zacks)
04:42PM	OPKO Health: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
08:00AM	OPKO Health's ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic Indications (GlobeNewswire)
Oct-28-25 08:00AM	OPKO Health's ModeX Therapeutics Begins Clinical Trial of MDX2004 for the Treatment of Advanced Cancers (GlobeNewswire)
Oct-23-25 01:56PM	Here's Why You Should Add OPKO Health Stock to Your Portfolio (Zacks)
Oct-22-25 04:05PM	OPKO Health to Report Third Quarter 2025 Financial Results on October 29 (GlobeNewswire)
Oct-01-25 01:44PM	OPKO Health, Inc. (OPK)'s ModeX Division Pushes Four Immuno-Oncology Candidates into Phase 1 (Insider Monkey)
Sep-17-25 08:52AM	LH Stock Rises on Acquisition of BioReference Health's Select Assets (Zacks)
Sep-15-25 08:30AM	Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Sep-11-25 12:20PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Aug-17-25 06:23PM	OPKO Health (OPK) Advances EBV Vaccine and GLP-1 Pipeline While Streamlining Diagnostics (Insider Monkey)
Aug-08-25 04:05PM	Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-06-25 03:27PM	RFK Jr. Ordered the HHS to Stop Funding mRNA Vaccine Development. The Edict Hit a Biotech Working on an Unrelated Treatment. (Barrons.com)
Aug-04-25 10:01AM	Opko Health (OPK) Reports Fiscal Q2 2025 Results (Insider Monkey) +6.72%
Aug-01-25 12:20PM	OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands (Zacks) -7.03%
06:47AM	OPKO Health (OPK) to Present Short Bowel Syndrome Treatment in Prague (Insider Monkey)
Jul-31-25 07:00PM	Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics (Zacks)
05:45PM	OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:45PM	OPKO Health: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Jul-24-25 04:05PM	OPKO Health to Report Second Quarter 2025 Financial Results on July 31 (GlobeNewswire)
Jul-23-25 11:25AM	OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX) (Insider Monkey)
Jul-08-25 08:00AM	OPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN Congress (GlobeNewswire)
Jul-07-25 09:10AM	H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3 (Insider Monkey)
Jun-25-25 11:00AM	OPKO Health to Participate in the 3rd Annual Piper Sandler Virtual Obesity Symposium (GlobeNewswire)
08:00AM	OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting (GlobeNewswire)
Jun-24-25 03:52PM	Piper Sandler Reiterates a Buy Rating on Opko Health (OPK) With a $3 PT (Insider Monkey)
Jun-13-25 12:37PM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Jun-09-25 08:00AM	OPKO Health's ModeX Therapeutics Announces Formation of Scientific Advisory Board with Leaders at the Forefront of Immunology and Oncology Drug Development (GlobeNewswire)
May-15-25 08:00AM	OPKO Health to Participate in Two Upcoming Investor Conferences (GlobeNewswire) +5.56%
May-01-25 12:43PM	OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands (Zacks)
08:57AM	Q1 2025 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents)
03:17AM	OPKO Health Inc (OPK) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial ... (GuruFocus.com)
Apr-30-25 07:52PM	OPKO Health, Inc. (OPK) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:30PM	OPKO Health (OPK) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:50PM	OPKO Health (OPK) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:47PM	OPKO Health: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Apr-22-25 09:35AM	Down -24.31% in 4 Weeks, Here's Why OPKO Health (OPK) Looks Ripe for a Turnaround (Zacks)
Apr-17-25 09:38AM	Labcorp Holdings: Regaining Credibility (Seeking Alpha)
08:00AM	OPKO Health to Report First Quarter 2025 Financial Results on April 30, 2025 (GlobeNewswire)
Apr-11-25 04:05PM	NextPlat Provides Statement on U.S. Tariff Impact on its E-Commerce Development Program (PR Newswire)
Apr-04-25 08:00AM	OPKO Health Announces $100 Million Increase to its Existing Share Repurchase Program (GlobeNewswire)
Mar-28-25 09:35AM	Here's Why You Should Retain OPKO Health Stock in Your Portfolio (Zacks)
Mar-18-25 11:37AM	Opko and Entera focus on oral care for obesity and metabolic disorders (Pharmaceutical Technology)
Mar-17-25 08:00AM	OPKO Health and Entera Bio Enter into Collaboration Agreement to Advance Oral GLP-1/Glucagon Tablet Candidate into the Clinic to Treat Obesity and Metabolic Disorders (GlobeNewswire)
Mar-14-25 06:59PM	Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. (Barrons.com)
12:07PM	Is OPKO Health, Inc. (OPK) The Best Stock Under $3 to Buy Now? (Insider Monkey)
Mar-12-25 12:10PM	Labcorp to acquire certain assets of Opko Healths BioReference Health (TipRanks)
11:06AM	Truist remains bullish on Labcorp after another nice strategic acquisition (TipRanks)
Mar-11-25 07:00AM	Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses (PR Newswire)
Feb-28-25 09:01AM	Q4 2024 OPKO Health Inc Earnings Call (Thomson Reuters StreetEvents) +6.75%
02:35AM	OPKO Health Inc (OPK) Q4 2024 Earnings Call Highlights: Strong Pharmaceutical Growth and ... (GuruFocus.com)
Feb-27-25 10:45PM	Opko Health (OPK) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00PM	OPKO Health (OPK) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	OPKO Health (OPK) Beats Q4 Earnings and Revenue Estimates (Zacks)
05:58PM	OPKO Health: Q4 Earnings Snapshot (Associated Press Finance)

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment manages the clinical laboratory operations of BioReference. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and their global pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Ph.D.Dr. Phillip Frost M.D.

Ph.D.Dr. Jane H. Hsiao M.B.A.

President & Vice Chairman of the BoardDr. Elias Adam Zerhouni M.D.

Senior VPMr. Adam E. Logal

J.D.Mr. Steven D. Rubin Esq.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PAGANELLI JOHN A	Director	Mar 20 '26	Buy	1.14	10,000	11,350	394,340	Mar 20 04:25 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 21 '25	Buy	1.33	580,000	768,807	216,706,448	Nov 21 05:07 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 20 '25	Buy	1.33	580,000	771,328	216,126,448	Nov 20 06:10 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 19 '25	Buy	1.31	580,000	759,115	215,546,448	Nov 19 05:02 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Nov 18 '25	Buy	1.27	533,300	678,906	214,966,448	Nov 18 05:18 PM
FROST PHILLIP MD ET AL	CEO & Chairman	Oct 31 '25	Buy	1.42	150,000	213,435	214,386,448	Oct 31 05:15 PM

Open in Screener

BCDA

BioCardia Inc

1.01

Oct 13 • 10:39 AM ET -0.01 (-0.98%)

Healthcare Biotechnology USA Nano NASD

Peers: AIM APRE BIVI CALC CVM KAPA KPRX NEUP GOVX JAGX

| Held by: VXF VTI

Index	-
Market Cap	15.29M
Enterprise Value	11.46M
Income	-7.34M
Sales	0.00M
Book/sh	0.18
Cash/sh	0.27
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	17
IPO	Nov 13, 1996

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.61
P/C	3.71
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	2.09
Current Ratio	2.09
Debt/Eq	0.11
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-0.76
EPS next Y	-0.52
EPS next Q	-0.13
EPS this Y	48.78%
EPS next Y	18.25%
EPS next 5Y	31.52%
EPS past 3/5Y	50.34% 43.92%
Sales past 3/5Y	- -
EPS Y/Y TTM	63.72%
Sales Y/Y TTM	-100.00%
EPS Q/Q	67.06%
Sales Q/Q	-
Earnings	Aug 12 AMC
EPS/Sales Surpr.	27.78% -

Insider Own	23.74%
Insider Trans	4.93%
Inst Own	9.03%
Inst Trans	9.98%
ROA	-214.47%
ROE	-1803.19%
ROIC	-271.81%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-5.34%
SMA50	-4.22%
SMA200	-8.25%
Trades

Shs Outstand	14.98M
Shs Float	11.54M
Short Float	5.37%
Short Ratio	2.27
Short Interest	0.62M
52W High	1.80 -43.89%
52W Low	0.75 34.67%
Volatility	5.03% 7.60%
ATR (14)	0.07
RSI (14)	43.47
Beta	0.68
Rel Volume	0.47
Avg Volume	272.43K
Volume	28,648

Perf Week	-4.72%
Perf Month	-15.13%
Perf Quarter	15.27%
Perf Half Y	-14.41%
Perf YTD	-19.20%
Perf Year	-33.11%
Perf 3Y	-84.70%
Perf 5Y	-97.76%
Perf 10Y	-99.43%
Recom	1.00
Target Price	15.50
Prev Close	1.02
Price	1.01
Change %	-0.98%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-16-21	Downgrade	Dawson James	Buy → Neutral

Oct-07-26 09:00AM	BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting (GlobeNewswire)
Oct-01-26 09:15AM	BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix Catheter (GlobeNewswire)
Sep-23-26 09:15AM	BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission (GlobeNewswire)
Sep-10-26 08:30AM	BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-24-26 08:30AM	BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval (GlobeNewswire)
01:04AM	Loading…
Aug-13-26 01:04AM	BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... (GuruFocus.com) +5.56%
Aug-12-26 09:00PM	BioCardia, Inc. Q2 2026 Earnings Call Summary (Moby) -5.59%
04:05PM	BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results (GlobeNewswire)
Aug-05-26 03:16PM	BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 (GlobeNewswire)
Jun-18-26 08:00AM	BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities (GlobeNewswire)
Jun-08-26 08:00AM	BioCardia Announces $4.4 Million Financing (GlobeNewswire) -10.68%
Jun-05-26 12:25PM	Why Did BCDA Stock Surge More Than 50% Today? (Stocktwits) +12.08%
10:31AM	BioCardia Shares Rally After FDA Supports Regulatory Path for Heart Failure Therapy (BCDA) (InvestorsHub)
08:00AM	FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF (GlobeNewswire)
May-28-26 08:00AM	BioCardia Announces Japan PMDA Record Of Advice Supports Regulatory Submission For Approval Of CardiAMP Cell Therapy For Ischemic Heart Failure (GlobeNewswire)
08:00AM	Loading…
May-21-26 08:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency (GlobeNewswire)
May-19-26 08:00AM	BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase (GlobeNewswire) +5.64%
May-16-26 08:30AM	BioCardia, Inc. Q1 2026 Earnings Call Summary (Moby)
01:00AM	BioCardia Inc (BCDA) Q1 2026 Earnings Call Highlights: Breakthroughs in Cardiac Therapy and ... (GuruFocus.com)
May-15-26 08:00AM	BioCardia Reports First Quarter 2026 Business Highlights and Financial Results (GlobeNewswire) -7.34%
May-11-26 05:10PM	BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 (GlobeNewswire)
May-08-26 08:00AM	BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways (GlobeNewswire)
Apr-28-26 08:00AM	BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures (GlobeNewswire)
Apr-20-26 08:00AM	BioCardia and Japan PMDA Align on Acceptability of CardiAMP Clinical Data to Support Regulatory Approval in Ischemic Heart Failure (GlobeNewswire) +5.93%
Apr-02-26 10:11AM	BioCardia Files Request for Meeting With FDA to Discuss Accelerated Approval Pathway for CardiAMP System in Ischemic Heart Failure (GlobeNewswire)
Mar-26-26 08:30AM	BioCardia, Inc. Q4 2025 Earnings Call Summary (Moby)
Mar-24-26 11:01PM	BioCardia Inc (BCDA) Q4 2025 Earnings Call Highlights: Promising Clinical Results Amid ... (GuruFocus.com)
04:05PM	BioCardia Reports 2025 Business Highlights and Financial Results (GlobeNewswire)
Mar-19-26 07:47PM	BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026 (GlobeNewswire)
Mar-17-26 06:00AM	BioCardia Announces Pre-Submission Approval Package for Helix Transendocardial Delivery Catheter Accepted by FDA (GlobeNewswire)
08:00AM	Loading…
Mar-03-26 08:00AM	BioCardia Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire) -5.92%
Feb-10-26 09:15AM	BioCardia Files Pre-Submission for FDA Approval of Helix Transendocardial Delivery Catheter for Therapeutic and Diagnostic Agent Delivery to the Heart (GlobeNewswire)
Feb-03-26 08:00AM	BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT) (GlobeNewswire)
Dec-16-25 08:00AM	BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA (GlobeNewswire)
Dec-03-25 08:00AM	BioCardia Announces Election of New Board Director, Marvin Slosman and Completion of Term for Outgoing Director, Dr. Richard Krasno (GlobeNewswire)
Dec-01-25 08:30AM	BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress (GlobeNewswire)
Nov-24-25 08:15AM	BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality (GlobeNewswire)
Nov-12-25 04:40PM	BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
Nov-10-25 08:30AM	BioCardia Announces Henry Ford Health Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Nov-05-25 07:29PM	BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025 (GlobeNewswire)
Oct-30-25 08:00AM	BioCardia Announces University of Wisconsin Enrolls Their First Patient in Phase 3 CardiAMP HF II Cell Therapy Pivotal Trial (GlobeNewswire)
Oct-02-25 08:00AM	BioCardia Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Sep-22-25 08:00AM	BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Sep-18-25 09:15AM	BioCardia Announces Pricing of Up To $12 Million Public Offering (GlobeNewswire) -23.78%
07:00AM	BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up (GlobeNewswire)
Sep-04-25 09:00AM	BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 (GlobeNewswire)
Aug-13-25 08:00AM	BioCardia and CART-Tech Announce Exclusive Partnership to Develop and Commercialize Heart3D Fusion Imaging for Interventional Cardiology (GlobeNewswire) +6.90%
Aug-11-25 09:15AM	BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results (GlobeNewswire) -6.15%
Aug-06-25 03:18PM	BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 (GlobeNewswire) -5.52%
Aug-04-25 06:00AM	BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP Cell Therapy for Heart Failure and Helix Transendocardial Delivery Catheter (GlobeNewswire) -7.98%
Jul-24-25 09:00AM	BioCardia Submits Request for Clinical Data Review Meeting with Japan PMDA To Discuss Approval Pathway for CardiAMP Cell Therapy in Ischemic Heart Failure (GlobeNewswire)
Jul-16-25 08:45AM	Henry Ford Health Initiates Patient Enrollment for BioCardia's CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction (GlobeNewswire)
Jun-25-25 08:00AM	BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
May-21-25 08:30AM	BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025 (GlobeNewswire)
May-15-25 03:16AM	BioCardia Inc (BCDA) Q1 2025 Earnings Call Highlights: Progress in Cardiac Cell Therapy Amid ... (GuruFocus.com) -16.25%
May-14-25 04:05PM	BioCardia Reports First Quarter 2025 Business Highlights and Financial Results (GlobeNewswire)
May-09-25 04:28PM	BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025 (GlobeNewswire)
May-06-25 08:00AM	BioCardia Initiates Patient Enrollment at University of Wisconsin at Madison for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
May-02-25 11:03AM	First subject enrolled in BioCardias Phase III heart failure therapy trial (Clinical Trials Arena) -5.96%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks) -9.24%
09:00AM	BioCardia Announces First Patient in Phase 3 Randomized Controlled Double-Blind CardiAMP HF II Clinical Trial of the Company's Lead Cell Therapy for Treatment of Heart Failure (GlobeNewswire)
Apr-16-25 05:45AM	DSMB recommends continuation of BioCardias cell therapy trial for heart failure (Clinical Trials Arena) -6.83%
Apr-15-25 08:30AM	BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1/2 Clinical Trial (GlobeNewswire)
Apr-14-25 06:52AM	Emory begins enrolment for BioCardias trial of ischemic heart failure therapy (Clinical Trials Arena)
Apr-11-25 09:15AM	BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study (GlobeNewswire)
Apr-01-25 08:24AM	Q4 2024 BioCardia Inc Earnings Call (Thomson Reuters StreetEvents) -15.75%
03:03AM	BioCardia Inc (BCDA) Q4 2024 Earnings Call Highlights: Strategic Cost Reductions and Promising ... (GuruFocus.com)
Mar-31-25 11:32PM	ACC 25: Biocardias CardiAMP trial fails but cell therapy potential remains (Clinical Trials Arena) -9.29%
11:30PM	BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript (Seeking Alpha)
01:39PM	BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today (GlobeNewswire)
08:00AM	Biocardia Phase 3 CardiAMP-HF Trial of Novel Cardiac Cell Therapy for Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, and Improved Quality of Life at Two Years (GlobeNewswire)
Mar-26-25 04:30PM	BioCardia Reports 2024 Business Highlights and Financial Results (GlobeNewswire) +5.10%
Mar-25-25 09:05AM	What To Expect From BioCardia Inc (BCDA) Q4 2024 Earnings (GuruFocus.com)
Mar-21-25 08:30AM	BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 (GlobeNewswire) +7.69%
Mar-10-25 09:15AM	BioCardia Announces Japanese Patent for Helix Biotherapeutic Delivery System (GlobeNewswire)
Feb-27-25 09:15AM	BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Feb-13-25 08:30AM	BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) (GlobeNewswire)
Jan-31-25 07:16AM	BioCardia upgraded to Buy from Neutral at Alliance Global Partners (TipRanks) +6.47%
Jan-27-25 09:15AM	BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions (GlobeNewswire)
Dec-17-24 07:00AM	BioCardia Announces Commercial Availability of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Dec-04-24 08:30AM	BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure (GlobeNewswire)
Nov-14-24 02:13AM	BioCardia Inc (BCDA) Q3 2024 Earnings Call Highlights: Breakthroughs and Challenges in Cardiac ... (GuruFocus.com) -14.26%
Nov-13-24 04:05PM	BioCardia Reports Third Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Nov-06-24 07:00AM	BioCardia to Host Q3 2024 Corporate Update and Financial Results Conference Call on November 13, 2024 (GlobeNewswire)
Oct-28-24 09:00AM	BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure (GlobeNewswire) +8.68%
Oct-09-24 06:19PM	BioCardia Inc (BCDA) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges (GuruFocus.com)
Sep-18-24 08:30AM	BioCardia Regains Full Compliance with Nasdaq Listing Requirements (GlobeNewswire) +10.39%
Sep-09-24 04:05PM	BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +6.17% +6.64%
Aug-30-24 08:00AM	BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -24.13%
Aug-29-24 08:30AM	BioCardia Announces FDA Market Clearance of Morph DNA Steerable Introducer Product Family (GlobeNewswire) +82.73%
Aug-21-24 07:00AM	FDA Approves CardiAMP Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment (GlobeNewswire) -12.91%
Aug-13-24 04:30PM	BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results (GlobeNewswire)
Aug-07-24 07:00AM	BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024 (GlobeNewswire) +5.95%
Jul-30-24 07:00AM	BioCardia Submits for FDA Approval of Morph DNA Steerable Introducer Product Family (GlobeNewswire)
Jul-25-24 07:00AM	Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure (GlobeNewswire)
Jul-17-24 07:00AM	BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application (GlobeNewswire)
Jul-08-24 07:00AM	CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes for the Treatment of Acute Myocardial Infarction (GlobeNewswire)
Jun-10-24 07:32AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -7.80%
Jun-07-24 07:00AM	BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach (GlobeNewswire) -14.78%
Jun-04-24 07:52AM	BCDA Stock Earnings: BioCardia Misses EPS, Misses Revenue for Q2 2023 (InvestorPlace)

BioCardia, Inc. is a clinical-stage biotherapeutic company, which engages in the business of developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its pipeline includes CardiAMP, CardiALLO, PulmALLO, Helix Biotherapeutic Delivery System, and Morph DNA and AVANCE Steerable Introducers. The company was founded on January 12, 1994 and is headquartered in Sunnyvale, CA.

CEODr. Peter A. Altman Ph.D.

Chief Financial OfficerMr. David McClung

Senior Vice President of DevicesMr. Edward M. Gillis

Investor Relations ExecutiveMs. Miranda Peto Benvenuti

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Altman Peter	President and CEO	Sep 29 '26	Buy	1.03	1,000	1,030	384,885	Sep 30 06:51 PM
Altman Peter	President and CEO	Sep 23 '26	Buy	1.05	1,900	1,995	383,885	Sep 23 08:14 PM
Altman Peter	President and CEO	Sep 03 '26	Buy	1.09	800	872	381,985	Sep 04 09:30 PM
Altman Peter	President and CEO	Aug 17 '26	Buy	0.93	5,400	5,022	381,115	Aug 18 12:14 PM
Altman Peter	President and CEO	Aug 13 '26	Buy	0.92	1,900	1,748	375,785	Aug 13 05:43 PM
Altman Peter	President and CEO	Jul 29 '26	Buy	0.78	5,000	3,900	373,885	Jul 29 09:05 PM
Altman Peter	President and CEO	Jul 17 '26	Buy	0.83	500	415	368,885	Jul 20 04:16 PM
Altman Peter	President and CEO	Jul 14 '26	Buy	0.88	2,800	2,464	366,885	Jul 15 04:40 PM
Altman Peter	President and CEO	Jul 15 '26	Buy	0.86	1,500	1,290	368,385	Jul 15 04:40 PM
Altman Peter	President and CEO	Jul 08 '26	Buy	0.97	5,500	5,335	367,485	Jul 10 06:18 PM
Altman Peter	President and CEO	Jul 10 '26	Buy	0.94	1,000	940	369,485	Jul 10 06:18 PM
Altman Peter	President and CEO	Jul 09 '26	Buy	0.90	1,000	900	368,485	Jul 10 06:18 PM
Altman Peter	President and CEO	Jul 08 '26	Buy	0.96	5,400	5,208	361,985	Jul 08 03:30 PM
STERTZER SIMON H	Director	Jun 22 '26	Buy	0.92	70,200	64,584	127,338	Jun 24 06:16 PM
STERTZER SIMON H	Director	Jun 23 '26	Buy	1.00	39,000	39,000	166,338	Jun 24 06:16 PM
Altman Peter	President and CEO	Jun 17 '26	Buy	0.85	1,500	1,275	299,766	Jun 22 06:09 AM
Altman Peter	President and CEO	Jun 18 '26	Buy	0.96	800	768	300,566	Jun 22 06:09 AM
Altman Peter	President and CEO	Jun 09 '26	Buy	0.85	5,000	4,250	298,266	Jun 09 05:37 PM
Altman Peter	President and CEO	May 20 '26	Buy	0.92	1,500	1,380	293,266	May 21 06:14 PM
Altman Peter	President and CEO	May 19 '26	Buy	0.95	200	190	291,766	May 21 06:14 PM
Altman Peter	President and CEO	May 18 '26	Buy	0.92	5,700	5,244	291,566	May 18 08:20 PM
Altman Peter	President and CEO	May 15 '26	Buy	1.02	5,100	5,202	285,866	May 15 05:46 PM
Altman Peter	President and CEO	Apr 29 '26	Buy	1.11	5,000	5,550	280,766	Apr 29 07:40 PM
Altman Peter	President and CEO	Apr 20 '26	Buy	1.23	600	738	275,366	Apr 22 05:04 PM
Altman Peter	President and CEO	Apr 21 '26	Buy	1.23	400	492	275,766	Apr 22 05:04 PM
Altman Peter	President and CEO	Mar 24 '26	Buy	1.24	600	744	274,466	Mar 26 08:05 PM
Altman Peter	President and CEO	Mar 25 '26	Buy	1.22	300	366	274,766	Mar 26 08:05 PM
Altman Peter	President and CEO	Feb 04 '26	Buy	1.13	5,000	5,650	273,866	Feb 04 05:47 PM
Altman Peter	President and CEO	Jan 20 '26	Buy	1.32	600	792	268,566	Jan 21 05:03 PM
Altman Peter	President and CEO	Jan 21 '26	Buy	1.34	300	402	268,866	Jan 21 05:03 PM
Altman Peter	President and CEO	Dec 17 '25	Buy	1.30	900	1,170	267,966	Dec 17 06:32 PM
Altman Peter	President and CEO	Dec 16 '25	Buy	1.37	200	274	267,066	Dec 17 06:32 PM

Peers: TSQ NCMI ADV NEXN QNST EVC CCO CRTO MGNI STGW

| Held by: VTI VXF BSVO IWC DFAC

Index	-
Market Cap	88.82M
Enterprise Value	116.54M
Income	-23.21M
Sales	202.15M
Book/sh	0.26
Cash/sh	0.22
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	186
IPO	Dec 27, 2007

P/E	-
Forward P/E	-
PEG	-
P/S	0.44
P/B	10.95
P/C	12.91
P/FCF	-
EV/EBITDA	-
EV/Sales	0.58
Quick Ratio	0.88
Current Ratio	0.88
Debt/Eq	4.27
LT Debt/Eq	0.83
Option/Short	No / Yes

EPS (ttm)	-0.77
EPS next Y	-0.04
EPS next Q	-0.09
EPS this Y	56.55%
EPS next Y	88.36%
EPS next 5Y	-
EPS past 3/5Y	51.36% -
Sales past 3/5Y	-16.70% -7.65%
EPS Y/Y TTM	43.57%
Sales Y/Y TTM	-12.05%
EPS Q/Q	34.78%
Sales Q/Q	8.37%
Earnings	Aug 10 AMC
EPS/Sales Surpr.	11.38% 8.54%

Insider Own	51.15%
Insider Trans	0.63%
Inst Own	30.96%
Inst Trans	-2.07%
ROA	-31.02%
ROE	-170.46%
ROIC	-156.41%
Gross Margin	22.44%
Oper. Margin	-8.14%
Profit Margin	-11.48%
SMA20	-10.19%
SMA50	-18.82%
SMA200	-13.67%
Trades

Shs Outstand	31.59M
Shs Float	15.44M
Short Float	0.38%
Short Ratio	1.80
Short Interest	0.06M
52W High	4.49 -37.42%
52W Low	1.70 65.29%
Volatility	6.54% 7.31%
ATR (14)	0.21
RSI (14)	34.84
Beta	0.69
Rel Volume	1.10
Avg Volume	32.57K
Volume	7,967

Perf Week	5.24%
Perf Month	-16.12%
Perf Quarter	-22.16%
Perf Half Y	-11.64%
Perf YTD	17.08%
Perf Year	34.45%
Perf 3Y	4.07%
Perf 5Y	-79.55%
Perf 10Y	-87.71%
Recom	2.00
Target Price	5.17
Prev Close	2.81
Price	2.81
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-23-26	Initiated	Lake Street	Buy	$5
May-10-22	Upgrade	Barrington Research	Mkt Perform → Outperform	$2.50
Mar-17-21	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-02-20	Upgrade	Barrington Research	Mkt Perform → Outperform	$4.50
Aug-26-20	Initiated	Canaccord Genuity	Buy	$5
Nov-12-19	Downgrade	Barrington Research	Outperform → Mkt Perform
May-09-19	Upgrade	ROTH Capital	Neutral → Buy	$5.50 → $8.50

Sep-08-26 09:05AM	Fluent Names Jeanniey Walden Chief Marketing Officer (GlobeNewswire)
Sep-02-26 08:03AM	Fluent, Inc. to Participate in 19th Annual Barrington Research Virtual Fall Investment Conference (GlobeNewswire)
Aug-19-26 08:03AM	Fluent, Inc. To Attend Lake Street Capital Markets 10th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-11-26 08:30AM	Fluent, Inc. Q2 2026 Earnings Call Summary (Moby)
01:03AM	Fluent Inc (FLNT) (Q2 2026) Earnings Call Highlights: Commerce Media Surges 90% as Company ... (GuruFocus.com)
04:54PM	Loading…
Aug-10-26 04:54PM	Fluent: Q2 Earnings Snapshot (Associated Press) +5.69%
04:05PM	Fluent Announces Second Quarter 2026 Financial Results; Commerce Media Solutions Annual Revenue Run Rate Exceeds $125 Million (GlobeNewswire)
Jul-29-26 08:03AM	Fluent, Inc. to Announce 2026 Second Quarter Financial Results and Host Earnings Conference Call on August 10, 2026 (GlobeNewswire)
Jul-21-26 08:03AM	Fluent, Inc. to Attend 46th Annual Canaccord Genuity Growth Conference (GlobeNewswire)
Jun-02-26 08:03AM	Fluent Inc. Subsidiary Trevant Launches as Creator Marketing Agency Built on Performance Discipline (GlobeNewswire) +17.05%
May-19-26 08:03AM	Fluent, Inc. Selected as Commerce Media Partner for BackpackSM Media by Sallie (GlobeNewswire)
May-14-26 08:30AM	Fluent, Inc. Q1 2026 Earnings Call Summary (Moby) +12.98%
01:02AM	Fluent Inc (FLNT) Q1 2026 Earnings Call Highlights: Strategic Expansion Amid Revenue Challenges (GuruFocus.com)
May-13-26 04:28PM	Fluent: Q1 Earnings Snapshot (Associated Press)
04:05PM	Fluent Announces First Quarter 2026 Financial Results; Commerce Media Solutions Annual Revenue Run Rate Exceeds $110 Million (GlobeNewswire)
08:30AM	Loading…
May-07-26 08:30AM	Fluent, Inc. to Announce 2026 First Quarter Financial Results and Host Earnings Conference Call on May 13, 2026 (GlobeNewswire) -5.14%
Mar-12-26 08:30AM	Fluent, Inc. Announces Partnership with Squire to Expand Commerce Media Solutions Beyond Traditional Retail Platforms (GlobeNewswire)
Mar-11-26 08:30AM	Fluent, Inc. to Participate in the 38th Annual ROTH Conference (GlobeNewswire)
Mar-09-26 11:00PM	Fluent Inc (FLNT) Q4 2025 Earnings Call Highlights: Record Growth in Commerce Media Solutions ... (GuruFocus.com)
05:35PM	Fluent (FLNT) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:33PM	Fluent: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Unaudited Fourth Quarter and Full-Year 2025 Financial Results; Commerce Media Solutions Revenue Run Rate Exceeds $105 Million and Represents 56% of Consolidated Enterprise Revenue (GlobeNewswire)
Mar-04-26 09:00AM	iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10-11, 2026 (ACCESSWIRE)
09:00AM	iAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 (ACCESSWIRE)
08:30AM	Fluent, Inc. to Participate in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2026 (GlobeNewswire)
Mar-02-26 08:30AM	Fluent, Inc. to Announce 2025 Fourth Quarter and Full-Year Financial Results and Host Earnings Conference Call on March 9, 2026 (GlobeNewswire)
Feb-24-26 08:30AM	Fluent Inc. Announces Three Years of Growth and Strategic Progress for Commerce Media Solutions (GlobeNewswire)
Feb-18-26 05:15PM	Omnicom (OMC) Lags Q4 Earnings and Revenue Estimates (Zacks) +5.07%
10:00AM	Singular Research Emerging Growth & Value Leaders Webinar Thursday, February 19, 2026 (TMX Newsfile)
Feb-06-26 08:30AM	Fluent, Inc. Announces Sale of Non-Core Call Solutions Subsidiary to Accelerate Strategic Shift to High Growth Commerce Media Solutions Business (GlobeNewswire) +5.19%
08:30AM	Loading…
Jan-21-26 08:30AM	Fluent, Inc. Named a 2026 Ad Age Best Place to Work (GlobeNewswire) +5.28%
Dec-02-25 08:30AM	Fluent Inc. Announces New Credit Facility (GlobeNewswire) +6.25%
Nov-14-25 12:03AM	Fluent Inc (FLNT) Q3 2025 Earnings Call Highlights: Surging Commerce Media Solutions and ... (GuruFocus.com)
Nov-13-25 05:20PM	Fluent (FLNT) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:16PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Fluent Announces Third Quarter 2025 Financial Results; Commerce Media Solutions Annual Revenue Run Rate Exceeds $85 Million and Represents 40% of Consolidated Revenue (GlobeNewswire)
Nov-06-25 07:45AM	Teads Holding Co. (TEAD) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
Nov-04-25 09:15AM	Fluent, Inc. to Announce Third Quarter 2025 Financial Results and Host Earnings Conference Call on November 13, 2025 (GlobeNewswire)
Oct-21-25 06:20PM	Omnicom (OMC) Q3 Earnings and Revenues Beat Estimates (Zacks)
Oct-16-25 08:30AM	Rebuy Monetize Powered by Fluent Accelerates Merchant Growth as Partnership Scales Across Shopify (GlobeNewswire)
Sep-17-25 08:30AM	Fluent Named to Crain's New York Business 2025 Best Places to Work List (GlobeNewswire) -5.21%
Sep-02-25 08:30AM	Fluent, Inc. to Participate in 18th Annual Barrington Research Virtual Fall Investment Conference (GlobeNewswire) -7.98%
Aug-27-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +9.55%
08:30AM	Fluent, Inc. Expands Data Intelligence & Data Collaboration Capabilities with Strategic Databricks Partnership and Key Leadership Hire (GlobeNewswire)
Aug-20-25 03:06AM	Fluent Inc (FLNT) Q2 2025 Earnings Call Highlights: Navigating Revenue Declines with Strategic ... (GuruFocus.com) -12.72%
Aug-19-25 06:20PM	Fluent (FLNT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
05:19PM	Fluent: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Fluent Announces Second Quarter 2025 Financial Results; Commerce Media Solutions Annual Revenue Run Rate Exceeds $80 Million (GlobeNewswire)
04:04PM	Fluent Announces $10.3 Million Private Placement of Securities (GlobeNewswire)
Aug-18-25 09:19AM	Fluent Inc (FLNT) Q2 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Aug-14-25 05:40PM	Gambling.com Group Limited (GAMB) Q2 Earnings and Revenues Beat Estimates (Zacks)
08:30AM	Fluent, Inc. Adds Authentic Brands Group to Partner Network, Powering Post-Purchase Monetization Across Brand Portfolio (GlobeNewswire)
Aug-13-25 08:30AM	Fluent, Inc. to Announce 2025 Second Quarter Financial Results and Host Earnings Conference Call on August 19, 2025 (GlobeNewswire) +7.52%
Aug-11-25 08:30AM	Fluent, Inc. to Attend 45th Annual Canaccord Genuity Growth Conference (GlobeNewswire)
Aug-07-25 08:44PM	FLINT Announces Transformational Recapitalization (GlobeNewswire)
07:45AM	Teads Holding Co. (TEAD) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Aug-06-25 07:05PM	Deluxe (DLX) Q2 Earnings Beat Estimates (Zacks)
Jul-31-25 05:00PM	FLINT Announces Second Quarter 2025 Financial Results (GlobeNewswire) -8.30%
May-29-25 08:30AM	Fluent, Inc. Expands Board of Advisors, Tapping Industry Experts for Commerce Media Growth (GlobeNewswire)
May-16-25 10:03AM	Q1 2025 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
03:14AM	Fluent Inc (FLNT) Q1 2025 Earnings Call Highlights: Strategic Growth in Commerce Media Amid ... (GuruFocus.com)
May-15-25 05:55PM	Fluent (FLNT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Fluent Announces First Quarter 2025 Financial Results; Strategic Pivot Accelerates with Growth of Commerce Media Solutions (GlobeNewswire)
May-14-25 09:59AM	Fluent Inc (FLNT) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-12-25 12:00PM	Fluent, Inc. to Announce 2025 First Quarter Financial Results and Host Earnings Conference Call on May 15, 2025 (GlobeNewswire)
May-08-25 05:00PM	FLINT Announces First Quarter 2025 Financial Results (GlobeNewswire)
08:30AM	Fluent, Inc. and Rebuy Partner to Unlock Post-Purchase Advertising for Shopify Merchants (GlobeNewswire)
Apr-25-25 09:40AM	Is Fluent (FLNT) Stock Outpacing Its Business Services Peers This Year? (Zacks)
Apr-23-25 07:28AM	New Strong Buy Stocks for April 23rd (Zacks) +12.90%
Apr-15-25 08:30AM	Fluent, Inc. Unveils Enhanced Identity Graph to Power Smarter Personalization and Campaign Performance (GlobeNewswire)
Mar-25-25 08:45AM	Fluent announces $5M private offering (TipRanks) +5.19%
Mar-24-25 08:30AM	Fluent, Inc. Announces $5.0 Million Private Offering (GlobeNewswire)
Mar-01-25 02:58AM	Q4 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Fluent Inc (FLNT) Q4 2024 Earnings Call Highlights: Navigating Challenges with Commerce Media Growth (GuruFocus.com)
Feb-28-25 09:10AM	Fluent (FLNT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	Fluent Announces Unaudited Fourth Quarter and Full-Year 2024 Financial Results (GlobeNewswire)
Feb-24-25 08:00PM	Fluent, Inc. to Announce Unaudited 2024 Fourth Quarter and Full-Year Financial Results and Host Earnings Conference Call on February 28, 2025 (GlobeNewswire) +5.49%
Feb-19-25 08:30AM	Fluent, Inc. Appoints Adrian Stack as Chief Product Officer; Accelerates AI-Powered Innovation in Commerce Media (GlobeNewswire)
Feb-05-25 08:30AM	Fluent, Inc. Survey Finds That Shoppers Embrace Post-Purchase Ads, Citing Personalization & Relevance as Key Benefits (GlobeNewswire)
Jan-27-25 12:00PM	Fluent, Inc. Named to Ad Age's 2025 Best Places to Work List (GlobeNewswire)
Jan-17-25 03:34PM	Global Value Investment Corporation's Interim CEO and President JP Geygan Appointed to Fluent, Inc.'s Board of Directors (GlobeNewswire)
Jan-07-25 08:30AM	Fluent, Inc. Announces Commerce Media Partnerships with Top-Tier Brands (GlobeNewswire) +6.04%
Dec-06-24 03:17PM	Why Is Fluent, Inc. (FLNT) Among The Best Advertising Stocks to Buy According to Hedge Funds? (Insider Monkey) +5.75%
Nov-29-24 05:58PM	Fluent, Inc. Announces $5.75 Million Registered Direct Offering and $2.75 Million Concurrent Private Offering (GlobeNewswire)
Nov-19-24 04:00PM	Fluent, Inc. Files New Investor Presentation and Makes Available on Company Website (GlobeNewswire) -5.32%
Nov-15-24 01:04PM	Q3 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -6.62%
02:15AM	Fluent Inc (FLNT) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic Shifts Amid ... (GuruFocus.com)
Nov-14-24 05:12PM	Fluent: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Fluent Announces Third Quarter 2024 Financial Results; Strategic Pivot Accelerates with Growth of Commerce Media Solutions (GlobeNewswire)
Nov-13-24 02:30PM	Fluent, Inc. to Announce 2024 Third Quarter Financial Results on November 14, 2024 (GlobeNewswire) -5.33%
Sep-10-24 10:00AM	Ryan Perfit Appointed Chief Financial Officer of Fluent, Inc. (GlobeNewswire)
Sep-06-24 08:30AM	Fluent, Inc. to Participate in the 17th Annual Barrington Research Virtual Fall Investment Conference (GlobeNewswire)
Aug-22-24 09:40AM	Are Investors Undervaluing Fluent (FLNT) Right Now? (Zacks)
Aug-20-24 08:11AM	Q2 2024 Fluent Inc Earnings Call (Thomson Reuters StreetEvents) -9.67%
Aug-19-24 05:10PM	Fluent (FLNT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Fluent Announces Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-15-24 10:00AM	Fluent, Inc. to Announce 2024 Second Quarter Financial Results on August 19, 2024 (GlobeNewswire)
Jul-12-24 08:30AM	Fluent, Inc. Announces Strategic Partnership with US Retailer, Hy-Vee, and Its Retail Media Network, RedMedia, to Enhance Customer Experience (GlobeNewswire)
Jun-28-24 08:30AM	Fluent, Inc. Announces Inclusion in Russell Microcap Index (GlobeNewswire) +7.76%
May-28-24 09:40AM	Is Fluent (FLNT) Stock Undervalued Right Now? (Zacks)

Fluent, Inc. engages in the provision of digital marketing services. It operates through the following segments: Fluent, Call Solutions, and AdParlor. The Fluent segment includes delivering data and performance-based marketing executions. The company was founded by Ryan Schulke and Matthew Conlin in 2001 and is headquartered in New York, NY.

Chief Executive OfficerMr. Donald Huntley Patrick

Co-FounderMr. Ryan Schulke

Co-FounderMr. Matthew Conlin

CFO and Principal Financial & Accounting OfficerMr. Ryan Macnab Perfit

Chief Marketing OfficerMs. Jeanniey Walden

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Sep 14 '26	Buy	3.38	12,376	41,831	3,229,627	Sep 16 09:06 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Aug 14 '26	Sale	4.15	600	2,490	3,218,566	Sep 16 09:06 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Aug 28 '26	Sale	3.58	665	2,381	3,217,399	Sep 16 09:06 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Aug 17 '26	Sale	4.05	500	2,025	3,218,066	Sep 16 09:06 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Sep 01 '26	Sale	3.23	148	478	3,217,251	Sep 16 09:06 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Aug 25 '26	Sale	4.15	2	8	3,218,064	Sep 16 09:06 PM
GEYGAN JAMES	Director	Sep 14 '26	Buy	3.38	12,376	41,831	3,137,960	Sep 16 09:06 PM
GEYGAN JAMES	Director	Aug 14 '26	Sale	4.15	600	2,490	3,126,899	Sep 16 09:06 PM
GEYGAN JAMES	Director	Aug 28 '26	Sale	3.58	665	2,381	3,125,732	Sep 16 09:06 PM
GEYGAN JAMES	Director	Aug 17 '26	Sale	4.05	500	2,025	3,126,399	Sep 16 09:06 PM
GEYGAN JAMES	Director	Sep 01 '26	Sale	3.23	148	478	3,125,584	Sep 16 09:06 PM
GEYGAN JAMES	Director	Aug 25 '26	Sale	4.15	2	8	3,126,397	Sep 16 09:06 PM
Graff David Allen	Director	Sep 10 '26	Sale	3.00	25,000	75,000	95,438	Sep 14 04:30 PM
Graff David Allen (FLNT)	Director	Sep 10 '26	Proposed Sale	3.00	25,000	75,000		Sep 10 05:05 PM
Schulke Ryan	Chief Strategy Officer	Sep 04 '26	Buy	3.08	2,823	8,684	4,156,617	Sep 09 08:30 AM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Jun 24 '26	Option Exercise	0.00	78,425	39	3,219,175	Jun 26 04:30 PM
GEYGAN JAMES	Director	Jun 24 '26	Option Exercise	0.00	67,059	34	3,127,507	Jun 26 04:30 PM
GEYGAN JAMES	Director	Jun 24 '26	Option Exercise	0.00	11,366	6	101,053	Jun 26 04:30 PM
Schulke Ryan	Chief Strategy Officer	Jun 23 '26	Option Exercise	0.00	655,895	328	4,153,857	Jun 25 05:06 PM
Conlin Matthew	Chief Customer Officer	Jun 25 '26	Option Exercise	0.00	454,648	227	3,009,027	Jun 25 05:06 PM
Conlin Matthew	Chief Customer Officer	Jun 23 '26	Option Exercise	0.00	85,714	43	2,554,391	Jun 25 05:06 PM
Conlin Matthew	Chief Customer Officer	Jun 25 '26	Option Exercise	0.00	57,143	29	498,474	Jun 25 05:06 PM
Patrick Donald Huntley	Chief Executive Officer	Jun 23 '26	Option Exercise	0.00	26,788	13	558,794	Jun 25 05:05 PM
GEYGAN JAMES	Director	Jun 12 '26	Buy	2.75	60,183	165,606	3,100,838	Jun 16 04:30 PM
GEYGAN JAMES	Director	Jun 12 '26	Buy	2.78	1,185	3,297	59,591	Jun 16 04:30 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Jun 12 '26	Buy	2.75	61,368	168,903	3,151,044	Jun 16 04:30 PM
Conlin Matthew	Chief Customer Officer	Jun 01 '26	Buy	2.07	5,000	10,350	2,468,677	Jun 02 09:00 AM
Schulke Ryan	Chief Strategy Officer	Jun 01 '26	Buy	2.07	5,000	10,350	3,497,995	Jun 02 09:00 AM
Patrick Donald Huntley	Chief Executive Officer	May 22 '26	Sale	2.58	19,230	49,640	312,455	May 27 09:39 PM
Patrick Donald Huntley	Chief Executive Officer	May 26 '26	Sale	2.48	286	711	312,169	May 27 09:39 PM
Perfit Ryan MacNab	Chief Financial Officer	May 26 '26	Sale	2.59	9,604	24,908	19,334	May 27 09:39 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Mar 13 '26	Buy	3.47	65,148	226,142	3,089,676	Mar 16 09:55 PM
GLOBAL VALUE INVESTMENT CORP.	10% Owner	Mar 12 '26	Buy	3.49	17,207	59,980	3,024,528	Mar 16 09:55 PM
GEYGAN JAMES	Director	Mar 13 '26	Buy	3.47	65,148	226,142	3,040,655	Mar 16 09:55 PM
GEYGAN JAMES	Director	Mar 12 '26	Buy	3.49	17,207	59,980	2,975,632	Mar 16 09:55 PM
GEYGAN JAMES	Director	Mar 13 '26	Buy	3.47	125	434	58,406	Mar 16 09:55 PM

Open in Screener

COCP

Cocrystal Pharma Inc

1.02

Oct 13 • 10:40 AM ET -0.04 (-3.77%)

Healthcare Biotechnology USA Nano NASD

COCP Cocrystal Pharma Inc daily Stock Chart

Peers: CMMB CVKD HIND INAB LEXX MTVA NCEL OSRH XCUR HCWB

| Held by: VTI VXF

Index	-
Market Cap	19.65M
Enterprise Value	18.75M
Income	-9.94M
Sales	0.33M
Book/sh	0.08
Cash/sh	0.12
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	10
IPO	Apr 01, 2008

P/E	-
Forward P/E	-
PEG	-
P/S	59.54
P/B	13.47
P/C	8.77
P/FCF	-
EV/EBITDA	-
EV/Sales	56.82
Quick Ratio	1.24
Current Ratio	1.24
Debt/Eq	1.29
LT Debt/Eq	0.95
Option/Short	No / Yes

EPS (ttm)	-0.76
EPS next Y	-0.47
EPS next Q	-0.18
EPS this Y	7.05%
EPS next Y	34.48%
EPS next 5Y	6.87%
EPS past 3/5Y	45.26% 17.90%
Sales past 3/5Y	- -
EPS Y/Y TTM	38.55%
Sales Y/Y TTM	-
EPS Q/Q	-13.61%
Sales Q/Q	-
Earnings	Aug 17
EPS/Sales Surpr.	-39.39% -

Insider Own	33.53%
Insider Trans	1.33%
Inst Own	5.77%
Inst Trans	15.22%
ROA	-151.10%
ROE	-311.68%
ROIC	-488.83%
Gross Margin	37.27%
Oper. Margin	-3063.64%
Profit Margin	-3011.52%
SMA20	-9.91%
SMA50	-9.53%
SMA200	-7.84%
Trades

Shs Outstand	13.79M
Shs Float	12.81M
Short Float	1.37%
Short Ratio	3.18
Short Interest	0.18M
52W High	2.03 -49.75%
52W Low	0.76 34.21%
Volatility	3.00% 5.90%
ATR (14)	0.06
RSI (14)	35.25
Beta	1.58
Rel Volume	2.33
Avg Volume	55.13K
Volume	28,681

Perf Week	-8.11%
Perf Month	-12.82%
Perf Quarter	6.25%
Perf Half Y	-33.33%
Perf YTD	4.19%
Perf Year	-3.77%
Perf 3Y	-44.57%
Perf 5Y	-91.09%
Perf 10Y	-99.41%
Recom	1.00
Target Price	7.00
Prev Close	1.06
Price	1.02
Change %	-3.77%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-08-20	Initiated	H.C. Wainwright	Buy	$5

Sep-18-26 09:48AM	A norovirus breakthrough?; another womens healthtech haul (Pharma Voice) +6.14%
Sep-15-26 08:56AM	Cocrystal Pharmas new CEO hopes to crack the norovirus code (Pharma Voice)
Sep-09-26 07:00AM	Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment (GlobeNewswire) +5.08%
Aug-31-26 11:39AM	Cocrystal Pharma: The Strategic Reset Investors May Be Missing (Exec Edge) +5.45%
Aug-17-26 11:17AM	Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors (GlobeNewswire)
07:00AM	Loading…
Aug-03-26 07:00AM	Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health (GlobeNewswire) +14.63%
Jun-03-26 07:00AM	Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer (GlobeNewswire)
May-26-26 08:00AM	Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza (GlobeNewswire)
May-15-26 08:00AM	Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-30-26 04:05PM	Cocrystal Pharma Presentation at ICAR 2026 Highlights Mechanism of Action and Clinical Advancement of CDI-988 for the Prevention and Treatment of Norovirus Infection (GlobeNewswire)
Apr-02-26 10:30AM	BC-Most Active Stocks (Associated Press) +48.04%
08:00AM	Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive (GlobeNewswire)
Mar-31-26 08:00AM	Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-09-26 08:00AM	First Subjects Dosed in Cocrystal Pharma's Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment (GlobeNewswire)
Feb-19-26 08:00AM	Cocrystal Pharma's First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026 (GlobeNewswire)
08:00AM	Loading…
Dec-18-25 08:00AM	Cocrystal Pharma Receives IRB Approval from Emory University School of Medicine for Phase 1b Human Challenge Study with CDI-988 for Prevention and Treatment of Norovirus (GlobeNewswire)
Dec-01-25 08:00AM	Cocrystal Pharma to Present at the Noble Capital Markets' 21st Emerging Growth Equity Conference (GlobeNewswire)
Nov-14-25 08:00AM	Cocrystal Pharma Reports Third Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Oct-30-25 08:00AM	Cocrystal Pharma Insiders Purchase $1.03 Million in Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-27-25 08:00AM	Cocrystal Pharma Receives NIH SBIR Award to Advance its Influenza Inhibitor Program (GlobeNewswire)
Oct-02-25 08:00AM	Cocrystal Pharma to Present at Noble Capital Markets Emerging Growth Virtual Equity Conference (GlobeNewswire)
Sep-15-25 04:30PM	Cocrystal Pharma, Inc. Announces Closing of Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -9.49% -7.69%
Sep-12-25 09:43AM	Cocrystal Pharma, Inc. Announces Up To $13 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.72%
08:00AM	Cocrystal Pharma Showcases CDI-988, the First Oral Antiviral in Development for Norovirus Infection, in a Podium Presentation at the International Calicivirus Conference (GlobeNewswire)
Sep-08-25 08:00AM	Cocrystal Pharma Receives FDA IND Clearance for Challenge Study of Oral Broad-Spectrum Protease Inhibitor CDI-988, a Potential First Antiviral for Norovirus Prevention and Treatment (GlobeNewswire)
Sep-03-25 08:00AM	Cocrystal Pharma to Participate at the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-14-25 08:00AM	Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Aug-05-25 08:00AM	Cocrystal Pharma Presents Phase 1 Results for Pan-Viral Inhibitor CDI-988 at Department of Defense Medical Conference (GlobeNewswire) -14.95%
Jul-10-25 08:00AM	Cocrystal Pharma to Present Data from Phase 1 Study of First-in-Class Norovirus Protease Inhibitor CDI-988 at the 9th International Calicivirus Conference (GlobeNewswire)
Jun-05-25 08:00AM	Cocrystal Pharma's Novel Norovirus Antiviral to be Presented at Department of Defense Medical Conference (GlobeNewswire)
08:00AM	Loading…
May-29-25 08:00AM	Cocrystal Pharma's Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain (GlobeNewswire) +8.74%
May-28-25 08:00AM	Cocrystal Pharma to Participate in Noble Capital Markets' 2025 Emerging Growth Virtual Equity Conference (GlobeNewswire)
May-15-25 08:00AM	Cocrystal Pharma Reports First Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Apr-24-25 08:00AM	Cocrystal Pharma's Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants (GlobeNewswire)
Apr-16-25 08:00AM	Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference (GlobeNewswire)
Mar-31-25 08:00AM	Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-14-25 08:35AM	Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-12-25 01:12PM	Life Sciences Investor Forum Agenda Announced for March 13th (GlobeNewswire)
Mar-06-25 08:00AM	Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025 (GlobeNewswire)
Jan-08-25 08:00AM	Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections (GlobeNewswire) +6.50%
Jan-02-25 06:34AM	Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial (Clinical Trials Arena) +14.85%
Dec-31-24 02:03PM	Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement (GuruFocus.com) -37.85%
08:00AM	Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344 (GlobeNewswire)
Nov-13-24 08:00AM	Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Oct-31-24 08:00AM	Cocrystal Pharma's Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins (GlobeNewswire)
Sep-26-24 08:00AM	Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts (GlobeNewswire)
Aug-19-24 04:05PM	Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences (GlobeNewswire) +15.38% -9.05%
Aug-15-24 03:00PM	CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event (ACCESSWIRE)
Aug-14-24 08:00AM	Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire) -10.53%
Jul-18-24 08:00AM	Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor (GlobeNewswire)
Jun-20-24 08:00AM	New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows (GlobeNewswire)
Jun-07-24 09:55AM	Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy? (Zacks)
May-13-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q1 2024 (InvestorPlace)
08:00AM	Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
May-01-24 08:00AM	Enrollment Completed in Phase 2a Study with Cocrystal Pharma's Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza (GlobeNewswire)
Mar-28-24 01:53PM	COCP Stock Earnings: Cocrystal Pharma Beats EPS for Q4 2023 (InvestorPlace) -6.67%
08:00AM	Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs (GlobeNewswire)
Mar-19-24 08:00AM	Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A (GlobeNewswire)
Mar-05-24 08:30AM	Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap (ACCESSWIRE)
Jan-04-24 08:00AM	Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates (GlobeNewswire)
Dec-06-23 08:00AM	Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-29-23 08:00AM	Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Nov-27-23 08:00AM	Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023 (GlobeNewswire) +17.12%
Nov-13-23 08:00AM	Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Nov-09-23 08:00AM	Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast (GlobeNewswire)
Oct-31-23 08:00AM	Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344 (GlobeNewswire) +5.25%
Oct-02-23 12:14PM	COCP: Cocrystal Pharma doses 1st subjects in the important CDI-988 clinical trial. (Zacks)
Sep-28-23 08:00AM	Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus (GlobeNewswire)
Sep-05-23 08:00AM	Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire) -8.38%
Aug-16-23 09:11AM	COCP: Cocrystal Pharma reports 2nd quarter 2023 financial results and provides updates on drug pipeline. (Zacks)
Aug-14-23 08:00AM	Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Aug-08-23 08:00AM	Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead (GlobeNewswire) +7.39%
May-31-23 08:00AM	Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988 (GlobeNewswire)
May-17-23 09:26AM	COCP: Cocrystal Pharma reports 1st quarter 2023 financial results and provides updates on drug pipeline. (Zacks Small Cap Research) -5.88%
May-15-23 08:00AM	Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire) -5.28%
May-04-23 04:05PM	Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-24-23 08:00AM	Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors (GlobeNewswire) +6.05%
Apr-18-23 08:00AM	Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference (GlobeNewswire)
Apr-10-23 08:30AM	Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +12.95%
Mar-31-23 10:05AM	COCP: UPDATE: Cocrystal Pharma announces full year 2022 financial results and provides drug program updates. (Zacks Small Cap Research) +5.85%
Mar-29-23 08:00AM	Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs (GlobeNewswire)
Mar-22-23 01:03PM	COCP: UPDATE: Cocrystal Pharma announced several program updates and investor events. (Zacks Small Cap Research)
08:00AM	Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023 (GlobeNewswire)
Jan-26-23 08:00AM	Cocrystal Pharma Announces Participation in Virtual Investor Events (GlobeNewswire) -6.62%
Jan-23-23 09:00AM	Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast (Newsfile)
Dec-19-22 08:00AM	Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire) -11.39%
Dec-01-22 04:05PM	Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022 (GlobeNewswire)
Nov-17-22 01:38PM	Cocrystal Pharma Posts Favorable Safety Data From Oral Antiviral Against Influenza A (Benzinga)
08:00AM	Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A (GlobeNewswire)
Nov-15-22 11:19AM	COCP: UPDATE: Cocrystal Pharma releases 2022 3rd quarter results and provides an update on the current pipeline programs. (Zacks Small Cap Research)
Nov-14-22 08:00AM	Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs (GlobeNewswire)
Nov-02-22 08:00AM	Cocrystal Pharma to Participate in Two Investor Conferences in November (GlobeNewswire) +13.41%
Nov-01-22 04:05PM	Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza (GlobeNewswire)
Oct-26-22 08:00AM	Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharmas Oral Antiviral Candidate CC-42344 (GlobeNewswire)
Oct-19-22 08:00AM	Cocrystal Pharma to Present at the LD Micro Main Event XV (GlobeNewswire)
Oct-13-22 08:00AM	Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022 (GlobeNewswire)
Oct-11-22 11:51AM	Cocrystal Pharma Advances One Of Its COVID-19 Antiviral Treatment Candidate (Benzinga) -9.02%
08:00AM	Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19 (GlobeNewswire)
Oct-05-22 08:00AM	Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference (GlobeNewswire)
Oct-03-22 04:05PM	Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split (GlobeNewswire) -13.65%

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create first- and best-in-class antiviral drugs. The company was founded in 2008 and is headquartered in Bothell, WA.

Co-FounderProf. Roger D. Kornberg Ph.D.

Chief Scientific OfficerDr. Sam Lee Ph.D.

R.Ph.Mr. James R. Sapirstein M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FROST PHILLIP MD ET AL	Director	Aug 05 '26	Buy	0.98	10,000	9,816	1,993,551	Aug 06 05:11 PM
FROST PHILLIP MD ET AL	Director	Aug 03 '26	Buy	0.94	75,000	70,590	1,983,551	Aug 05 04:10 PM
FROST PHILLIP MD ET AL	Director	Feb 24 '26	Buy	1.00	20,000	19,952	1,908,551	Feb 25 04:10 PM
FROST PHILLIP MD ET AL	Director	Feb 06 '26	Buy	0.95	50,000	47,280	1,888,551	Feb 09 04:10 PM
FROST PHILLIP MD ET AL	Director	Dec 31 '25	Buy	0.95	50,000	47,275	1,838,551	Jan 02 04:10 PM
FROST PHILLIP MD ET AL	Director	Dec 30 '25	Buy	0.97	20,000	19,310	1,788,551	Dec 31 04:10 PM
FROST PHILLIP MD ET AL	Director	Dec 26 '25	Buy	0.97	40,000	38,944	1,768,551	Dec 29 09:24 AM
FROST PHILLIP MD ET AL	Director	Dec 24 '25	Buy	0.97	25,000	24,258	1,728,551	Dec 29 09:24 AM
FROST PHILLIP MD ET AL	Director	Nov 26 '25	Buy	0.99	4,000	3,975	1,703,551	Nov 28 09:00 AM
FROST PHILLIP MD ET AL	Director	Nov 25 '25	Buy	0.94	20,000	18,812	1,699,551	Nov 25 08:17 PM

OPK

Opko Health Inc

BCDA

BioCardia Inc

FLNT

Fluent Inc

COCP

Cocrystal Pharma Inc

Upgrade your Finviz experience